Lataa...
The cost-effectiveness of a modestly effective HIV vaccine in the United States
BACKGROUND: The recent RV144 clinical trial showed that an ALVAC/AIDSVAX prime-boost HIV vaccine regimen may confer partial immunity in recipients and reduce transmission by 31%. Trial data suggest that efficacy may initially exceed 70% but decline over the following 3.5 years. Estimating the potent...
Tallennettuna:
| Päätekijät: | , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3156325/ https://ncbi.nlm.nih.gov/pubmed/21510996 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2011.04.013 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|